Rare cancer patients could gain better access to targeted drugs through new study
NCT ID NCT04814095
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study follows 30 adults with incurable rare cancers or rare genetic changes who are already taking a Health Canada-approved targeted therapy that is not publicly funded. Researchers will track quality of life, survival, and tumor response over time to generate real-world evidence. The goal is to help health agencies decide whether to fund these treatments for broader use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help rare cancer patients access funded targeted therapies by providing real-world evidence of their benefits.
- What could go wrong
- This is a small, early-stage observational study (30 participants) with no control group, so results may not be conclusive or generalizable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
BC Cancer
RECRUITINGVancouver, British Columbia, V5Z4E6, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?
- A simple screening program could transform cancer aftercare
- Can simple positive activities boost Well-Being in cancer care?